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Sexual dysfunction associated with hypertension or antihypertensive 
therapies may impact the ability of patients to stay on therapy and lead to 
deterioration in patients' quality of life. Therefore, it is important for 
practitioners to become familiar with the wide variation in sexual side effects 
produced by antihypertensive agents and to discuss the potential occurrence 
of these side effects with their patients. In many cases, a change in the 
patient's drug regimen may help patients overcome specific sexual side 
effects experienced with certain drugs. Practitioners should consider 
selecting an antihypertensive therapy that is highly effective in lowering 
blood pressure and at the same time preserves patients' quality of life. The 
effect of medications on sexual function remains controversial. Some blinded 
trials report little difference between placebo and specific medications, 
whereas other studies indicate that antihypertensive medications increase 
sexual dysfunction, which has an impact on quality of life. Recent evidence 
suggests that losartan, an angiotensin II antagonist, is not typically associated 
with development of sexual dysfunction and may actually positively impact 
several indices of sexual function (erectile function, sexual satisfaction, and 
frequency of sexual activity) as well as perceived quality of life. Thus, 
angiotensin II antagonists may offer a therapeutic option to prevent or correct 
erectile dysfunction in patients with hypertension. The favorable effects of 
these agents on sexual function may be related, in part, to their ability to 
block angiotensin II, which has recently become recognized as an important 
mediator of detumescence and possibly erectile dysfunction. 
 




















Dysfonction sexuelle associée à l’hypertension ou aux thérapies 
antihypertensives pourrait provoquer la capacité des patients de rester sur la 
thérapie et mener à la détérioration de la qualité de vie des patients.  Donc, il 
est important que les praticiens se familiarisent  avec des variations diverses 
des effets secondaires sexuels de médicament produit par des agents 
d’antihypertensif et de discuter la fréquence potentielle de ces effets 
secondaire avec leur patients.  À bien des cas, un changement dans le régime 
de la drogue de patient pourrait aider les patients à vaincre les effets 
secondaires sexuels spécifiques expérimentés avec certaines drogues.  Les 
praticiens devraient considérer le choix d’une thérapie antihypertensive qui 
est extrêmement efficace de baisser la tension artérielle et en même temps 
préserver la qualité de vie des patients.  Les effets du médicament sur la 
fonction sexuelle reste controversés.  Quelques tests aveugles raportent peu 
différence entre placebo et médications spécifiques, tandis que des autres 
études montrent que des médicaments d’antihypertensive augment la 
dysfunction sexuelle, qui a une influence sur la qualité de vie.  Des preuves 
récentes suggèrent que losatan, un angoitensine II antagonist,  n’est pas 
associé typiquement au développement de la dysfonction sexuelle et pourrait  
 










en fait positivement avoir un impact sur des indices divers de fonctionnement 
sexuel (fonction érectile, satisfaction sexuelle, et la fréquence d’activité 
sexuelle) aussi bien que la qualité de vie perçue.   Donc, angiotensine II 
antagonist pourrait donner une option thérapeutique pour éviter ou corriger la 
dysfonction érectile chez des patients atteints de l’hypertension.  Des effets 
favorables de ces agents sur la fonction sexuelle pourrait être semblable d’un 
côté, pour leur capacité de bloquer angiotensine II, qui est tout récemment 






Erectile dysfunction (ED) is the consistent inability to 
maintain a penile erection sufficient for adequate 
sexual relations. The effects of ED are profound and 
far-reaching, interfering with a man's self-esteem, 
interpersonal relationships, and overall sense of well-
being.1
Despite the well known benefits of effective long-
term antihypertensive drug therapy in reducing 
cardiovascular risk, almost three quarters of US adults 
with hypertension fail to achieve adequate blood 
pressure control.2 Almost half of the hypertensive 
patients have poor antihypertensive drug compliance 
in Nigeria.3, 4, 5 This statistic is, in part, attributable to 
the rate of discontinuation of antihypertensive 
medications due to the occurrence of troublesome side 
effects. Appearance of treatment-related side effects 
may actually make patients feel worse than they did 
before beginning antihypertensive therapy, 
particularly since most patients with hypertension are 
asymptomatic.6 As many as 70% of hypertensive 
patients who experience side effects are noncompliant 
with their antihypertensive medication, and patients 
experiencing a negative impact on their quality of life 
have a 40%-60% higher rate of therapy 
discontinuation than patients whose quality of life is 
unaffected.7,8 On the other hand, blood pressure 
control may be associated with quality of life 
improvement (patients feeling better). The inability of 
patients to stay on therapy in the long term may be 
one of the factors contributing to the development of 
hypertension-related complications. 
Sexual dysfunction induced by antihypertensive 
medications is one of the poorly recognized side 
effects impacting the patient's ability to stay on 
therapy. Moreover, this side effect of antihypertensive 
medications is strongly associated with an impaired 
quality of life.9-11 Many commonly prescribed 
antihypertensive medications may give rise to sexual 
dysfunction, which often presents in men as a 
decrease in libido, difficulty attaining or maintaining 
an erection, and ejaculation problems, and, in women, 
as a delay in orgasm.12,13 Not all classes of 
antihypertensive agents share the same risk of 
inducing sexual problems; certain types of 
antihypertensive medications are generally associated 
with a lower risk of sexual dysfunction than others.[6] 
In fact, recent studies suggest that angiotensin II 
antagonists (AIIAs) may actually improve erectile 
function and sexual activity in male hypertensive 
patients.14,15 The favourable effects of AIIAs on 
sexual function may be related to their ability to block 
angiotensin II (ANG II), which has been shown to 
terminate spontaneous erections when administered 
exogenously in an experimental model of penile 
function.16
In view of these observations, it is important for 
practitioners to be aware of the sexual side effects 
produced by antihypertensive agents so that the 
selected therapy may provide an optimum balance 




Association with antihypertensive agents and the 
dysmetabolic syndrome of high blood pressure 
 
Sexual dysfunction is a frequently encountered 
problem in patients with hypertension and may occur 
either as a side effect of some types of 
antihypertensive medications or as a component of the 
dysmetabolic syndrome of high blood pressure.9,17 In 
hypertensive males, sexual dysfunction may present 
in a variety of ways, including a decreased incidence 
of sexual activity, difficulty attaining or maintaining 
an erection, and problems in ejaculating.12 For the 
most part, sexual problems have been reported to 
occur more frequently in patients receiving 
antihypertensive medication than in those with either 
untreated hypertension or in normotension .12,14,18-20 
However, as discussed below, this finding is not 
universal.20 In the Treatment of Mild Hypertension 
Study (TOMHS),21 a placebo-controlled trial, there 
was no difference in the incidence of sexual 
dysfunction among several antihypertensive agents 
when compared to placebo at 4 years. At 1 year, 
however, a greater incidence was noted with a diuretic 
than with other drugs.21
The concept of hypertension as a dysmetabolic 
syndrome has brought to the forefront the frequent 
association of high blood pressure with dyslipidaemia, 
insulin resistance, coagulation disorders, and 
peripheral vascular disease.22 The anatomic and 
haemodynamic characteristics of the penile 
circulation make the process of penile tumescence 
inextricably linked to blood pressure, perfusion 
pressure, and vascular compliance. In this context, 
Toblli et al23 reported that cavernous-tissue vascular 
fibrosis was present in rats with spontaneous 
hypertension and that the degree of vascular sclerosis 
in the rat penis was highly correlated with the level of 
arterial pressure. These intriguing observations 
suggest a vasculogenic mechanism of erectile
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dysfunction in hypertensive subjects, since peripheral 
arterial disease has begun to be recognized as an early 
consequence or direct contributor to high blood 
pressure. 
In keeping with the new animal studies, the recent 
findings of Llisteri and colleagues14 demonstrate that 
erectile dysfunction in hypertensive patients aged 30-
65 years was associated with medications that had not 
been usually considered to impair sexual function. 
Thus, hypertension-related erectile dysfunction may 
be a consequence of a reduction in penile perfusion 
pressure associated with the decrease in systemic 
arterial pressure induced by antihypertensive 
medications in the presence of an already decreased 
penile vascular compliance. Under this scenario, 
erectile dysfunction may represent a previously 




Prevalence of sexual dysfunction in hypertensive 
patients 
 
Several reports collectively spanning more than three 
decades indicate that 2.4%-58% of hypertensive 
males experience one or more symptoms of sexual 
dysfunction of varying degrees of severity during 
antihypertensive drug therapy.12,14,18,19,21,24,25 It is also 
true, however, that hypertensive patients also 
experience sexual dysfunction prior to taking 
medication, when compared to normotensive subjects. 
This finding, while quite consistent with the 
physiologic changes noted in hypertensive 
individuals, is often neglected in the overall 
assessment of subjects and in the formulation of a 
therapeutic scheme. The large variations in the 
prevalence of sexual problems reported in the 
literature most likely reflect differences in study 
methodology (lack of control subjects), types of 
antihypertensive medications taken, the presence of 
confounding medications, age differences of study 
populations, and cultural and socioeconomic factors. 
In the clinical practice setting, the prevalence of 
sexual dysfunction is likely to be even higher than 
that reported in clinical trials because the personal 
nature of this problem often leads to an unwillingness 
of many patients and/or physicians to openly discuss 
this issue. 
Although most research on sexual dysfunction has 
focused almost exclusively on men, 26 women with 
hypertension are also at risk of developing sexual 
dysfunction. According to a 1994 survey, sexually 
active women aged 60-80 years who were receiving 
antihypertensive medications (atenolol, enalapril, or 
isradipine) experienced sexual dysfunction,  
manifested as a difficulty in achieving orgasm, 
inadequacy of vaginal lubrication, and diminished 
libido.13 However, in the absence of a control group of 
hypertensive women who were not receiving 
antihypertensive therapy, it is difficult to accurately 
assess the effect of antihypertensive medication on 
sexual functioning. 
 
Effect of sexual dysfunction on quality of life and 
compliance with treatment 
 
Sexual dysfunction associated with antihypertensive 
agents may impact the ability of patients to stay on 
therapy and lead to an impaired quality of life.9-11 
Sexual dysfunction is an important reason why 
patients discontinue antihypertensive medications, as 
exemplified by the findings of the Medical Research 
Council (MRC) trial in 17,354 hypertensive patients 
studied over 5.5 years.27 In this study, premature 
withdrawal due to impotence occurred at a 
significantly higher rate in patients receiving either a 
thiazide diuretic (p<0.001) or B blocker (p<0.001) 
than in placebo-treated patients (12.6% and 6.3% vs. 
1.3% per 1000 patient-years, respectively). However, 
it must be pointed out that the MRC study was of 
single-blind design, and thus the findings should be 
interpreted with caution. 
Sexual dysfunction associated with 
antihypertensive therapies may also impact the quality 
of life of hypertensive patients.8, 28 As early as 1982, 
Jachuck and colleagues29 reported an association of 
sexual dysfunction with impairment of quality of life 
in hypertensive patients treated primarily with 
diuretics, B blockers, or methyldopa (the last, is not 
recommended in antihypertensive therapy because of 
its high association with side effects and the 
emergence of better options). Approximately 78% of 
patients who had severe quality of life impairment 
(according to spouses' ratings) had a reduction in or 
no sexual interest. In contrast, only 38% of patients 
with mild impairment of quality of life had reduced 
sexual function. It must be noted, however, that not all 
studies have reported a relation between 
antihypertensive therapy and sexual dysfunction, and 
in one review of six randomized trials, short-term 
exposure to antihypertensive drugs was associated 
with a prevalence of self-reported impotence that was 
similar to that in placebo-treated patients.25 Further, in 
the Trial of Antihypertensive Interventions and 
Management (TAIM),30  a multicentre, randomized, 
placebo-controlled trial in patients with mild 
hypertension, low-dose antihypertensive drug therapy 
(with chlorthalidone or atenolol) actually improved, 
rather than impaired, quality of life. 
 
 
Types of antihypertensive therapy associated with 
sexual dysfunction 
 
Several widely prescribed antihypertensive agents, 
including diuretics, methyldopa, clonidine, 
guanethidine, and B-blockers (especially those that 
are nonselective), are known to cause sexual problems 
or exacerbate existing problems.9,31,32 However, not 
all classes of antihypertensive agents share the same 
risk of inducing sexual problems, and certain classes 
of antihypertensive agents tend to be associated with a 
higher prevalence of sexual dysfunction than 
others.9,15   Differences among the various classes of 
antihypertensive agents have been noted in men with
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respect to erectile dysfunction, decreased libido, 
impaired ejaculation, gynaecomastia, and priapism. 
Conclusions regarding an association between 
antihypertensive therapy and sexual dysfunction are 
limited by the fact that several of the studies were 
poorly controlled and results were based on 
questionnaires. This is one of the factors responsible 
for the lack of recognition of sexual dysfunction as a 
component of the hypertensive process rather than as 
a consequence of antihypertensive medications. 
Compared with placebo or other classes of 
antihypertensive agents, a higher prevalence of male 
sexual dysfunction has been reported in some studies 
of diuretics, including spironolactone, which inhibits 
dihydrotestosterone binding, and thiazide diuretics 
(e.g., chlorthalidone), as well as B 
blockers.12,15,21,24,33,34   Beta blockers (e.g., atenolol 
and propranolol) may potentially impact sexual 
functioning through a variety of mechanisms, 
including a reduction in central sympathetic outflow, 
impairment of vasodilation of the corpora cavernosa, 
effects on luteinizing hormone and testosterone 
secretion, and a tendency to produce sedation or 
depression, thereby causing a loss of libido.15,34 
However, as noted, deleterious effects of diuretics and 
B blockers on sexual function have not been 
consistently found, and several controlled studies, 
including TOMHS and a combined analysis of six 
randomized, blinded, prospective trials, have found 
little or no evidence for a greater risk of occurrence of 
adverse sexual sequelae between these agents and 
other antihypertensive medications.26,35,36 Variations 
in the design of the studies, the inclusion of a placebo 
control arm, and the characteristic of the population 
under investigation are factors adding to the 
difficulties in recognizing the nature of the 
mechanisms that associate sexual dysfunction with 
hypertension and its medications. 
Centrally acting antiadrenergic agents, such as 
methyldopa and clonidine, also give rise to male 
sexual dysfunction, possibly by decreasing 
sympathetic outflow as well as diminishing libido and 
ejaculation. Direct vasodilators, including hydralazine 
and minoxidil, may produce erectile dysfunction and 
priapism, but this appears to be uncommon.37  There 
is little evidence to suggest that calcium channel 
blockers (CCBs) result in erectile dysfunction, 
although impotence associated with verapamil has 
been described,38 and in one study, CCBs were second 
to angiotensin-converting enzyme (ACE) inhibitors in 
their association with erectile dysfunction.14 
Moreover, gynaecomastia and problems with 
ejaculation have been reported with CCB therapy.34,39
 
Evolving role of angiotensin II (ANG II) as a 
mediator of erectile dysfunction 
While the physiology of erection is a complex, 
neurovascular event regulated by psychologic and 
hormonal factors,32 corporal and vascular smooth 
muscle tone and contractility play a key role in 
modulating penile blood flow and, hence the erectile 
process. Erection occurs due to nitric oxide-mediated 
relaxation of corporal and arterial smooth muscle, 
allowing increased blood flow into the sinusoidal 
spaces.32 Nitric oxide, released from the endothelium 
and from noradrenergic, noncholinergic cavernous 
nerves during sexual stimulation, appears to be the 
principal mediator of erection, although vasoactive 
polypeptide and prostaglandins may also be 
involved.32,37 
Recent evidence suggests that ANG II may play 
an important role in detumescence and possibly 
erectile dysfunction.16,40  ANG II has been identified 
in human corpus cavernosum (primarily in endothelial 
cells lining blood vessels and smooth muscle bundles 
within the corpus cavernosum), where its tissue 
concentration is 200 times higher than plasma levels 
and 10 times higher than in aortic or mesenteric 
vessels.16 Superfused cavernosal tissue from human 
subjects undergoing penile prosthesis implantation 
synthesizes (presumably via local endothelial ACE) 
and spontaneously secretes ANG II. Local ACE may 
therefore regulate smooth muscle tone in a paracrine 
fashion via production of ANG II, which in turn 
stimulates contraction of corporal and vascular 
smooth muscle via an ANG II receptor. This 
constricts blood flow through the penile arteries and 
reopens the venous plexus, thereby allowing penile 
flaccidity to return. This mechanism is consistent with 
a recent study indicating that the ACE DD genotype 
(a deletion polymorphism in the ACE gene associated 
with high circulating and tissue levels of ACE) may 
represent an important risk factor for vasculogenic 
erectile dysfunction.40
The potential involvement of ANG II in regulating 
erectile function is illustrated by the results of Kifor 
and colleagues, 16 who utilized a canine model of 
penile erection. Intracavernosal administration of 
ANG II terminated spontaneous erections in 
anesthetized dogs, an effect similar to that obtained 
with epinephrine. Administration of the Angiotensin 
II Antagonist (AIIA) in the same model resulted in a 
dose-dependent increase in cavernosal pressure and 
relaxation of smooth muscle, and thus the 
development of an erection. These intriguing studies 
suggest that ANG II may be an important mediator of 
erectile function and may offer a mechanistic 
explanation for the improvement in erectile function 
as well as satisfaction and frequency of sexual activity 
observed in clinical studies in male hypertensive 





Occurrence of sexual dysfunction in patients with 
hypertension may not only negatively impact the 
ability of patients to stay on antihypertensive therapy, 
but can also lead to deterioration in quality of life. 
Therefore, it is important for practitioners to be aware 
of the wide variation in sexual side effects produced 
by antihypertensive agents and to be willing to discuss 
potential occurrence of these problems with patients. 
Practitioners should consider choosing an 
antihypertensive therapy with the lowest possible 
potential for sexual side effects in order to attain an
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optimum balance between antihypertensive efficacy 
and quality of life. Recent studies indicate that AIIAs 
may offer a therapeutic option to prevent or correct 
erectile dysfunction in patients with hypertension. 
AIIAs have been shown to positively impact several 
indices of sexual function and perceived quality of 
life, effects possibly attributable to blockade of the 
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